Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have been used, since their invention, as the first-line treatment of non-small-cell lung cancer (NSCLC) patients harboring EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.